ArticleBMC gastroenterology2025
Association of alpha-1 acid glycoprotein with hepatic steatosis and liver fibrosis among women: a population-based study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe alpha-1-acid glycoprotein (AGP) is a novel inflammatory biomarker, and inflammation has been implicated in hepatic steatosis and fibrosis. The objective of this study was to investigate the relationship between AGP and hepatic steatosis and hepatic fibrosis and to assess its value as a potential biomarker. METHODS AND
resultsIn this study, the authors used data from NHANES between 2017 and 2023, adopting a cross-sectional design. In the multivariate linear regression model, the natural logarithm of alpha-1-acid glycoprotein (Ln AGP) was considered in relation to CAP and LSM. Smooth curve fitting was performed to address potential nonlinear relationships. The study involved 2,608 adult women aged 18 to 49 years. Multivariate linear regression analysis indicated a significant positive association between Ln AGP and CAP (β = 17.80, 95% CI: 10.56–25.05; P < 0.0001), suggesting that higher AGP levels may be correlated with greater hepatic steatosis. However, no statistically significant linear association was found between Ln AGP and LSM (β = -0.40, 95% CI: -0.93 to 0.12; P = 0.1307). Importantly, subsequent analysis revealed a significant L-shaped nonlinear association, with an inflection point identified at an Ln AGP of 0.05 g/L. It is important to note that due to the cross-sectional design, these findings reflect associations rather than causal relationships.
conclusionsOur cross-sectional study found that elevated AGP concentrations are associated with greater hepatic steatosis (CAP; β = 17.80, 95% CI: 10.56–25.05; P < 0.0001), though this design cannot establish causality. For hepatic fibrosis (LSM), while no significant linear association was observed (β = -0.40, 95% CI: -0.93 to 0.12; P = 0.1307), a significant nonlinear L-shaped relationship was identified, indicating a complex association. These findings highlight the necessity for future research to investigate potential causal relationships between AGP and liver health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.